Nkarta Inc (NKTX) Stock Price, Quote & News

Company Profile

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for...

Industry: Biotechnology

Sector: Healthcare

Phone: 925 407 1049

Website: www.nkartatx.com

Address:

1150 Veterans Boulevard, South San Francisco, United States

Paulfrench Jul. 16 at 6:48 AM

$NKTX Yesterday's candlestick indicates that a slight retracement is likely before the price breaks out. It's possible that this has already occurred yesterday, however (the hourly chart suggests this is the case; see the commentary). In any case, the July 14th signal is too powerful for it not to have a bullish effect on the price in the medium term.

1 · Reply

Paulfrench Jul. 14 at 8:12 PM

$NKTX OK guys, congrats ! we've come out of the cloud from above, we're crossing the Kijun Sen line and all this with decreasing volume. This is a very powerful signal, we should quickly go up to the level above (200MA at $2.30) and then much higher as soon as there is news. 😉🫡

0 · Reply

Paulfrench Jul. 14 at 7:48 PM

$NKTX Hold on, brothers, this is definitely not the time to sell!

0 · Reply

hopeteen Jul. 14 at 10:38 AM

$NKTX Can anyone provide fundamental analysis on the stock?

0 · Reply

Paulfrench Jul. 13 at 1:01 PM

$NKTX The battle was intense last week, with conflicting signals coming one after another, and the situation isn't completely resolved. As long as we haven't managed to break through the Kijun Sen line (in brown), anything remains possible. However, Friday's candlestick gives us hope; the price is finally breaking through the 100MA, but not definitively (in my opinion). I think we'll need another attempt to erase the strength of this resistance... I still think next week will bring us some good news.

0 · Reply

Malandrosky Jul. 11 at 2:47 PM

$NKTX $ALLO how do $INKT results affect us? I think it’s bullish no?

1 · Reply

Paulfrench Jul. 10 at 4:36 PM

$NKTX On the 1h chart we have just crossed the 200MA without resistance from sellers...this could be the signal to move to the next level. Even if I did not expect this to happen today, I would have bet more on an increase in volume and a price that does not manage to cross 1.84 🤨... to be seen this evening🤔

2 · Reply

jjangles123 Jul. 10 at 12:51 PM

$NKTX nothing doing?

0 · Reply

Paulfrench Jul. 9 at 7:16 AM

$NKTX Yesterday's candle indicates that buyers have started to regain control, this does not mean that sellers have abandoned the level, there may still be a few days of resistance at $1.76 but I am convinced that we should find a bullish movement fairly quickly anyway. The goal for the coming days is to cross the brown line at $1.86 (Jijun sen) easily.

2 · Reply

jjangles123 Jul. 9 at 2:33 AM

$NKTX My evening chat with the GPT brought me here. How are we doing? Shall I entertain a position perchance?

1 · Reply

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

May 15, 2025, 3:46 PM EDT - 2 months ago

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

May 14, 2025, 4:01 PM EDT - 2 months ago

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Apr 1, 2025, 8:01 AM EDT - 3 months ago

Nkarta to Participate in an April Investor Conference

Mar 31, 2025, 10:41 AM EDT - 3 months ago

Nkarta: Grinding Lower, Trying To Find Support

Mar 31, 2025, 10:15 AM EDT - 3 months ago

Nkarta: Betting On The Turnaround

Mar 27, 2025, 12:50 PM EDT - 3 months ago

Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?

Mar 26, 2025, 4:01 PM EDT - 3 months ago

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Feb 25, 2025, 8:01 AM EST - 5 months ago

Nkarta to Participate in March Investor Conferences

Dec 5, 2024, 6:01 AM EST - 7 months ago

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Nov 26, 2024, 7:02 AM EST - 8 months ago

Nkarta to Participate in an Upcoming Investor Conference

Nov 7, 2024, 4:02 PM EST - 8 months ago

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Oct 8, 2024, 9:07 AM EDT - 10 months ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

AMN MRNA

Sep 3, 2024, 4:01 PM EDT - 11 months ago

Nkarta to Participate in Upcoming Investor Conference

Aug 14, 2024, 3:08 PM EDT - 11 months ago

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Aug 13, 2024, 9:03 PM EDT - 1 year ago

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Aug 13, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Jul 24, 2024, 6:00 AM EDT - 1 year ago

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Jul 16, 2024, 6:01 AM EDT - 1 year ago

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

Jun 27, 2024, 6:00 AM EDT - 1 year ago

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Jun 13, 2024, 4:01 PM EDT - 1 year ago

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

May 25, 2024, 2:20 AM EDT - 1 year ago

Nkarta: Finally An Attractive Valuation

May 9, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

Apr 27, 2024, 10:27 AM EDT - 1 year ago

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Apr 8, 2024, 12:55 PM EDT - 1 year ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 5, 2024, 3:35 PM EDT - 1 year ago

The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 3, 2024, 4:02 PM EDT - 1 year ago

Nkarta to Participate in Upcoming Investor Conferences

Mar 25, 2024, 4:03 PM EDT - 1 year ago

Nkarta: NK Cell Therapy Advancement On Two Fronts

Mar 25, 2024, 6:30 AM EDT - 1 year ago

Nkarta Announces Pricing of $240 Million Underwritten Offering

Mar 21, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Mar 13, 2024, 1:22 PM EDT - 1 year ago

Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders

Jan 25, 2024, 12:12 PM EST - 1 year ago

Nkarta: Possible Upside From H1 Update, If Positive

Dec 9, 2023, 8:31 PM EST - 1 year ago

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Nov 9, 2023, 4:02 PM EST - 1 year ago

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

Nov 7, 2023, 8:02 AM EST - 1 year ago

Nkarta to Participate at Upcoming Investor Conferences

Oct 17, 2023, 11:47 AM EDT - 1 year ago

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

Oct 17, 2023, 7:01 AM EDT - 1 year ago

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Oct 16, 2023, 4:01 PM EDT - 1 year ago

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

Aug 10, 2023, 7:01 AM EDT - 2 years ago

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

Aug 3, 2023, 8:02 AM EDT - 2 years ago

Nkarta to Participate at Upcoming Investor Conference

Jul 5, 2023, 4:02 PM EDT - 2 years ago

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

$Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia$

Jun 27, 2023, 7:01 AM EDT - 2 years ago

Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Jun 26, 2023, 4:01 PM EDT - 2 years ago

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program

Jun 10, 2023, 10:47 AM EDT - 2 years ago

Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

May 11, 2023, 4:02 PM EDT - 2 years ago

Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights

May 11, 2023, 4:01 PM EDT - 2 years ago

Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Apr 26, 2023, 7:00 AM EDT - 2 years ago

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

TNYA

Apr 17, 2023, 5:01 PM EDT - 2 years ago

Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting

Mar 30, 2023, 4:01 PM EDT - 2 years ago

Nkarta Announces Departure of Chief Financial & Business Officer

Paulfrench Jul. 16 at 6:48 AM

1 · Reply

Paulfrench Jul. 14 at 8:12 PM

0 · Reply

Paulfrench Jul. 14 at 7:48 PM

$NKTX Hold on, brothers, this is definitely not the time to sell!

0 · Reply

hopeteen Jul. 14 at 10:38 AM

$NKTX Can anyone provide fundamental analysis on the stock?

0 · Reply

Paulfrench Jul. 13 at 1:01 PM

0 · Reply

Malandrosky Jul. 11 at 2:47 PM

$NKTX $ALLO how do $INKT results affect us? I think it’s bullish no?

1 · Reply

Paulfrench Jul. 10 at 4:36 PM

2 · Reply

jjangles123 Jul. 10 at 12:51 PM

$NKTX nothing doing?

0 · Reply

Paulfrench Jul. 9 at 7:16 AM

2 · Reply

jjangles123 Jul. 9 at 2:33 AM

$NKTX My evening chat with the GPT brought me here. How are we doing? Shall I entertain a position perchance?

1 · Reply

RetirementByTrade Jul. 2 at 5:52 PM

$NKTX

1 · Reply

viking1111 Jun. 30 at 5:26 PM

$NKTX our stock and board need some life. This has been stagnant for months.

0 · Reply

misfit88 Jun. 27 at 11:20 AM

$NKTX loaded

1 · Reply

Paulfrench Jun. 24 at 9:31 AM

$NKTX I entered at $1.76, so the price should go down quite quickly! 🤣🤣🤣 In any case, yesterday's candle materializes a bearish VSA divergence (one more) it is the sign that buyers are gradually entering and testing the sellers, it is really the sign that we should see a bullish movement relatively quickly (I hope so in any case) 🤷‍♂️

4 · Reply

hopeteen Jun. 20 at 8:50 AM

$NKTX Any catalyst news in the near future?

1 · Reply

Paulfrench Jun. 17 at 8:43 AM

$NKTX Smells good guys! For me we have a clear signal of an upcoming bullish movement with possible support at $1.83 before taking off.

1 · Reply

BlakeCanyon50 Jun. 13 at 1:12 PM

$NKTX Tends to move on adverse market days.. Like Today…

0 · Reply

BlakeCanyon50 Jun. 11 at 5:07 PM

$NKTX Tick Tock Boys & Girls… 💥

0 · Reply

nightstocker15 Jun. 11 at 11:58 AM

$HSDT congrats to all that got in!! Gotta love profits to start the day! Don’t forget about $NKTX with over 5 bucks a share in cash on the books! Ripe for a huge bounce as well! 💪🥃🙌🤟🤝

0 · Reply

viking1111 Jun. 11 at 1:37 AM

$NKTX green days are always nice to see. We have been fooled though over and over after a run up then it pulls right back down. Looking at the chart I feel like I did months ago. This needs a strong pass and hold above 2.25 range, then head on up to the 200 ma. This hasn't been a fast mover, and that's ok if it can rebound. I sure want way more than the $2's.

0 · Reply

click_420 Jun. 10 at 3:43 PM

$NKTX starting a position here. How's the vibe

3 · Reply

anachartanalyst Jun. 10 at 3:02 PM

$NKTX https://anachart.com/wp-content/uploads/ana_temp/1749567703_soc-img.jpg

0 · Reply

Market Cap	134.11M
Revenue (ttm)	0.00
Net Income (ttm)	-108.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	511,000
Avg Vol	458,942
Day's Range	N/A - N/A
Shares Out	70.96M
Stochastic %K	64%
Beta	0.70
Analysts	Strong Sell
Price Target	$12.80